Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Liraglutide

Brand: Saxenda ®
NICE TA: 
Indication: As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of • ≥ 30 kg/m² (obese), or • ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No

Background

NOT recommended for use by the NHS in Lancashire.
There is insufficient evidence of long-term safety, sustained weight loss and cost effectiveness in patients using saxenda.

Recommendation

LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  Not recommended for prescribing on the NHS in Lancashire

Supporting documents:

New Medicine Review - Liraglutide (Saxenda ®) (453.2 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Black

Black

Black

Black

Black

Black